Outcome of COVID-19 infections in patients with adrenal insufficiency and excess

Background: Information on clinical outcomes of coronavirus disease 19 (COVID-19) infection in patients with adrenal disorders is scarce. Methods: A collaboration between the European Society of Endocrinology (ESE) Rare Disease Committee and European Reference Network on Rare Endocrine Conditions via the European Registries for Rare Endocrine Conditions allowed the collection of data on 64 cases (57 adrenal insufficiency (AI), 7 Cushing’s syndrome) th at had been reported by 12 centres in 8 European countries between January 2020 and Dec ember 2021. Results: Of all 64 patients, 23 were males and 41 females (13 of those children) with a median age of 37 and 51 years. In 45/57 (95%) AI cases, COVID -19 infection was confirmed by testing. Primary insufficiency was present in 45/57 p atients; 19 were affected by Addison’s disease, 19 by congenital adrenal hyperpla sia and 7 by primary AI (PAI) due to other causes. The most relevant comorbidities w ere hypertension (12%), obesity (n = 14%) and diabetes mellitus (9%). An increase by a median of 2. 0 (IQR 1.4) times the daily replacement dose was reported in 42 (74%) patie nts. Two patients were administered i.m. injection of 100 mg hydrocortisone, and 11/64 were admitted to the hospital. Two patients had to be transferred to the intensive care unit, one with a fatal outcome. Four patients reported persistent SARS-CoV-2 inf ection, all others complete remission. Conclusion: This European multicentre questionnaire is the first to collect data on the outcome of COVID-19 infection in patients with adrenal gland disorders. It suggests good clinical outcomes in case of duly dose adjustments and emphasiz es the importance of patient education on sick day rules.

Abstract licence: CC BY-NC

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.